In his "If I were king" talk at the Moments of Change conference, the medical director at Retreat Premier Addiction Treatment Centers advocated a balanced and comprehensive approach to combating the opioid crisis.
The FDA is alerting providers and patients of the dangers of combining MAT drugs with benzodiazepines, a move that follows a recent change in labeling requirements for buprenorphine to indicate patients may require indefinite treatment.
A 2016 physician survey on the prescribing of buprenorphine does indicate that counselors and other specialty providers could help physicians overcome reluctance to prescribe the opioid dependence treatment.
A Boston Medical Center study has found that just over one-quarter of adolescents and young adults diagnosed with an opioid use disorder from 2001-2014 received a prescription for buprenorphine or naltrexone.
The National Institute on Drug Abuse (NIDA) is funding a study that will determine whether direct observation of patients receiving buprenorphine treatment can improve retention in treatment and drug use outcomes.